Tirzepatide Microdosing Therapy
US$ 25.03
glp 1/gip agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Curious about the latest in
Description
89.American Diabetes Association Professional Practice C
2022 [cited 2024 Oct 14];7
10.1172/jci.insight.93382 Summary Keywords glucagon-like peptide-1 receptor agonists, ocular diseases, glaucoma, diabetic retinopathy, mechanism Citation Xie Z, Yang Z, Tian D and Chen Y (2025) Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
doi: 10.1007/s11064-017-2250-8 [DOI] [PubMed] [Google Scholar] 233
Cost effectiveness and equitable access will need careful consideration if GLP-1RAs are to be deployed more broadly in NDDs
Buteau J, Foisy S, Rhodes CJ, et al
